Introduction
============

Osteoporosis is a chronic and progressive metabolic skeletal disease characterized by low bone mass and deterioration of the microarchitecture of bone tissue, and it is associated with pain and disability \[[@b1-asj-2019-0230],[@b2-asj-2019-0230]\]. Fractures due to osteoporosis are a major cause of morbidity owing to associated pain and immobility, and these fractures increase mortality, with hip fractures associated with half of the deaths attributable to osteoporosis \[[@b3-asj-2019-0230]\]. Fragility fractures also place a considerable burden on healthcare resources.

Several pharmacological treatments for osteoporosis have been developed in the last 2 decades, and these were found to be effective for reducing the risk of fragility fractures in controlled clinical trials \[[@b4-asj-2019-0230],[@b5-asj-2019-0230]\]. As osteoporosis is a chronic condition that requires long-term treatment, poor persistence with and adherence to medication are key issues. To achieve efficacy and a successful treatment outcome in a real-world setting, therapies proven to be effective in clinical trials should be taken at the prescribed dose (adherence) and should be continued over the required course (persistence) \[[@b6-asj-2019-0230]\]. Non-persistence and nonadherence with osteoporosis therapy are associated with a high fracture risk of 30%--40% \[[@b7-asj-2019-0230],[@b8-asj-2019-0230]\]. Additionally, recent evaluations of fragility fractures have shown that lack of efficacy because of poor therapy persistence and/or adherence results in high economic cost and reduces health-related quality of life of patients \[[@b9-asj-2019-0230],[@b10-asj-2019-0230]\]. This is a major public health issue, and ensuring adherence and persistence of osteoporosis treatment is particularly challenging for healthcare professionals.

Denosumab (Prolia; Amgen, Thousand Oaks, CA, USA) is a fully human monoclonal antibody that selectively targets the RANK ligand and is an alternative antiresorptive treatment for osteoporosis \[[@b11-asj-2019-0230]\]. It is the first biological agent developed as an anti-osteoporosis drug, is administered by subcutaneous injection every 6 months, and has been authorized for the treatment of osteoporosis in Japan since 2013 \[[@b12-asj-2019-0230]\]. In clinical trials, denosumab has been shown to be well tolerated, increase bone mineral density (BMD), and greatly reduce fracture risk \[[@b12-asj-2019-0230]\]. Denosumab administered every 6 months in patients with severe osteoporosis was highly effective for decreasing fracture risk, with a 68% reduction in the incidence of new radiographic vertebral fractures in 3 years and a similar 69% reduction in the incidence of clinical vertebral fractures \[[@b13-asj-2019-0230]-[@b15-asj-2019-0230]\]. Therefore, denosumab is mainly used for patients with severe osteoporosis who might have high motivation for treatment, and the need for only semi-annual subcutaneous injection might improve the continuation rate. Regarding denosumab persistence, Silverman et al. \[[@b16-asj-2019-0230]\] found a 12-month discontinuation rate of 18% and Migliaccio et al. \[[@b17-asj-2019-0230]\] reported persistence rates of 83%, 69%, and 62% at 12, 18, and 24 months, respectively. However, no English-language articles have reported on denosumab persistence in the Japanese population, including young people, despite the importance of this issue in a superaging society. Therefore, the present study was designed to examine denosumab persistence for the treatment of osteoporosis among different age groups in a routine clinical setting in Japan.

Materials and Methods
=====================

1. Participants
---------------

The subjects were patients who started treatment with subcutaneous denosumab (Prolia) at 60 mg every 6 months in our department from July 2013 until December 2017 (data collection deadline). The inclusion criteria were use of denosumab for primary osteoporosis, bone density ≤70% of young adult mean (YAM), history of proximal femoral fracture or vertebral fracture, and other fragile fractures with bone density ≤80% of YAM. Patients with secondary osteoporosis due to steroid use were also included in the study. At the beginning of denosumab treatment, patients were provided instructions on the drug by the referring orthopedic specialist. All patients received dental treatment before receiving denosumab. The following information was collected: age, period of use, year of initiation, and cause of non-persistence. Persistence has been defined as the duration from initiation to discontinuation of therapy \[[@b18-asj-2019-0230]\]. In the present study, persistence was evaluated as a dichotomous variable measured at the end of a predefined period, with patients defined as "persistent" or "non-persistent." Persistence rates were calculated for all eligible patients \[[@b17-asj-2019-0230]\], and Kaplan-Meier curves were used to depict persistence over time in each age group. This study was approved by the Nagoya University Institutional Review Board (IRB approval no., 2018-377), and informed consent was obtained from all individual participants included in the study.

2. Statistical analysis
-----------------------

Demographic and clinical characteristics of the subjects are summarized in the results section. The persistence rate was estimated using Kaplan-Meier analysis. Continuous variables are expressed as mean±standard deviation, and categorical variables are expressed as absolute value and percentage. Differences between two groups were analyzed using Student t-test, and differences among three groups were analyzed using the Kruskal-Wallis test. All statistical analyses were performed using IBM SPSS ver. 22.0 (IBM Corp., Armonk, NY, USA). A *p*-value \<0.05 was considered significant in all analyses.

Results
=======

In the study period, we identified 101 patients (84 females \[83%\]) who were treated with denosumab. The basic characteristics of the cohort are shown in [Table 1](#t1-asj-2019-0230){ref-type="table"}. The median follow-up period was 23.6±14.2 months (range, 8.1--66.2 months). The age distribution of the patients is shown in [Fig. 1](#f1-asj-2019-0230){ref-type="fig"}. Among the patients, three were \<40 years old and two were \>90 years old, indicating a wide age range. There were 31 non-persistent patients, including 4 (20%), 9 (19%), and 18 (53%) aged \<60, 60--79, and ≥80 years, respectively. The reasons for non-persistence of denosumab are shown in [Table 2](#t2-asj-2019-0230){ref-type="table"}. The most common cause was transfer to another hospital (n=13), followed by interruption of outpatient visits (n=11), dental treatment (n=4), adverse events (n=2), and patient request (n=1). The adverse events were fatigue and nausea.

During the study period, the overall persistence rate at 60 months was 70% (70 patients). Kaplan-Meier analysis showed a slow decline of persistence to 85.3%, 78.38%, 74.1%, 71.3%, and 69.3% at 12, 24, 36, 48, and 60 months of follow-up, respectively ([Fig. 2](#f2-asj-2019-0230){ref-type="fig"}). With regard to age, persistence was significantly lower in patients aged ≥80 years than in those aged \<60 and 60--79 years (both *p*\<0.01) ([Fig. 3](#f3-asj-2019-0230){ref-type="fig"}). Additionally, there was a significant difference in age at the initiation of denosumab treatment between non-persistent (n=31) and persistent (n=77) patients (81.3 versus 72.8 years, *p*\<0.01) ([Fig. 4](#f4-asj-2019-0230){ref-type="fig"}).

Discussion
==========

In this study, we analyzed denosumab persistence in patients with osteoporosis. Information was collected from an orthopedic department at a single institution in Japan, and it included findings for young and old patients. Patients treated with denosumab are commonly motivated to receive osteoporosis treatment and thus are more adherent to this treatment \[[@b19-asj-2019-0230]\]. Clinical trials have shown high denosumab persistence \[[@b15-asj-2019-0230],[@b20-asj-2019-0230]\]. In a multicenter prospective study involving 935 postmenopausal women treated for osteoporosis in US and Canadian community practice, Silverman et al. \[[@b16-asj-2019-0230]\] found a 12-month discontinuation rate of 18%, whereas Migliaccio et al. \[[@b17-asj-2019-0230]\] reported persistence rates of 83%, 69%, and 62% at 12,18, and 24 months, respectively. In a retrospective study by Karlsson et al. \[[@b21-asj-2019-0230]\] using real-world data from the Swedish Prescribed Drug Register (n=2,315), the denosumab persistence rate was 83% at 12 months and 62% at 24 months. It should be noted that these studies mainly included postmenopausal women, and few studies included young people.

Persistence is a key factor for the successful management of chronic disorders, and long dosing intervals are thought to contribute to better treatment adherence and persistence \[[@b22-asj-2019-0230]\]. Therefore, understanding the factors that influence patient perceptions of osteoporosis treatment might allow improved education to increase persistence of drugs, including anti-osteoporotic drugs administered by injection, such as teriparatide and denosumab. Adequate patient monitoring, visit frequency, pharmacological schedule, and patient motivation can play important roles in enhancing persistence and increasing the effectiveness of anti-osteoporotic therapy \[[@b7-asj-2019-0230]\].

We noted high rates of denosumab persistence of 85.3% at 12 months and 69.3% at 60 months. Administration was discontinued for dental treatment in four cases. Another reason for non-persistence was transfer to another hospital to visit a doctor in the local neighborhood. In particular, our series included many patients aged over 90 years, and it was difficult for many of them to visit our institution. These patients preferred local medical treatment, and some who had high motivation for treatment and who had been adherent to denosumab might have continued with the treatment. Additionally, some patients discontinued visiting the outpatient clinic, and this was partly because of death in elderly patients with short life expectancy. Consideration of these factors would have increased the persistence rate. The two adverse events of fatigue and nausea were also associated with non-persistence. Based on our findings, the continuation rate might be increased by (1) performing dental examination before denosumab administration, (2) pre-prescribing drugs to prevent nausea as a complication, (3) providing patients with a good explanation of the necessity and efficacy of denosumab, and (4) providing assistance to families, especially with regard to elderly patients.

Among anti-osteoporosis drugs, denosumab, which selectively targets the RANK ligand, might be particularly useful in elderly people, considering its high efficacy for decreasing fracture risk and its simplicity of use with only a semi-annual subcutaneous injection. Because of aging of the society, it is likely that an increasing number of people aged over 90 years will receive denosumab. We found it difficult to follow such patients because our study was performed in a university hospital rather than a facility supporting home care. However, we suggest that patients aged over 90 years can take denosumab with sufficient compliance through follow-up by their primary doctors.

The present study has some limitations. First, the sample size was small in this retrospective series. Second, a follow-up BMD test could not be performed in all cases after denosumab administration, and thus, the therapeutic effect was not evaluated. Third, the study focused only on denosumab, and there was no control group receiving a different medication. Nevertheless, the study included male and female individuals of all ages, and data were collected for young and old patients. To our knowledge, this is the first English report to describe the persistence of denosumab and the causes of denosumab discontinuation, with a focus on Japan. Studies using prescription-based databases have several well-known limitations that might result in underestimation of persistence; however, in Japan, denosumab is injected subcutaneously by medical staff in a hospital, making the procedure and follow-up data more reliable.

Conclusions
===========

We found a high rate of persistence with denosumab therapy at a single institution in Japan. Persistence was significantly lower in patients aged ≥80 years than in patients of other ages, and strategies promoting persistence are needed for these elderly patients. Our findings might be indicators of future difficulties with therapy in a superaging population.
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###### 

Characteristics of the study population (n=101)

  Characteristic                                                          Value
  ----------------------------------------------------------------------- -----------
  Follow-up period (mo)^[a)](#tfn1-asj-2019-0230){ref-type="table-fn"}^   23.6±14.2
  Age (yr)^[b)](#tfn2-asj-2019-0230){ref-type="table-fn"}^                72.3±16.8
  Gender (female)                                                         84 (83)
  Year of initiation                                                      
   2013                                                                   7 (7)
   2014                                                                   15 (15)
   2015                                                                   20 (20)
   2016                                                                   27 (27)
   2017                                                                   32 (32)
  Non-persistence                                                         31 (31)

Values are presented as mean±standard deviation or number (%).

Time until censoring or non-persistence.

Age of patient at initiation of denosumab treatment.

###### 

Cause of non-persistence in different age groups (n=31)

  Cause of non-persistence                                                            Total     Age (yr)       
  ----------------------------------------------------------------------------------- --------- ---------- --- ----
  Transfer to another hospital                                                        13 (40)   2          4   7
  Interruption of outpatient visits^[a)](#tfn3-asj-2019-0230){ref-type="table-fn"}^   11 (34)   1          2   8
  Interruption due to dental treatment                                                4 (13)    1          1   2
  Adverse event                                                                       2 (6)     0          1   1
  Patient's request                                                                   1 (3)     0          1   0
  Total                                                                               31        4          9   18

Values are presented as number (%) or number.

The rate of interruption of outpatient visits was significantly greater in patients aged ≥80 yr (*p* \<0.05 by Kruskal-Wallis test).
